NXGL earnings analysis
What we found in NXGL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the current-quarter income statement, balance sheet, cash-flow statement, or segment disclosures, so revenue, margins, EPS, liquidity, and free cash flow cannot be quantified from the available filing content. The filing highlights substantial financing risk, with $14.7 million of convertible notes outstanding at 10% interest, rising to 18% upon default, alongside potential dilution. Additional concerns include a damages claim exceeding $1.75 million, up to $20.0 million of contingent Celularity payments, and ineffective disclosure controls as of June 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Remediation Plan for Material Weaknesses
- The company is pursuing remediation of two identified control deficiencies: journal entries were not subject to adequate review and approval, and one accounting employee had “super user” access to financial reporting systems.
- Celularity Portfolio Acquisition
- NexGel completed an April 2026 license acquisition from Celularity involving an exclusive license to a commercial-stage regenerative biomaterials portfolio, with $13.3 million of upfront consideration.
- Convertible Note Financing
- The company raised $7.375 million of gross proceeds from convertible notes issued on April 17, 2026, plus $1.21 million from notes issued on May 11, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Heavy Debt and Dilution Exposure
- Convertible notes payable outstanding totaled $14.7 million as of June 30, 2026. The notes carry 10% annual interest, increasing to 18% upon an event of default, and conversion prices are subject to downward adjustment.
- $1.75 Million-Plus Arbitration Claim
- The Bezalel Partners arbitration seeks damages in excess of $1.75 million, plus interest, attorneys’ fees and costs, related to an alleged breach of a Finder’s Fee Agreement.
- Acquisition Execution and Payment Risk
- The Celularity transaction may require up to an additional $20.0 million in contingent milestone payments, while the company cautions that anticipated commercialization benefits may not be realized on the expected timeline or at all.
- Material Internal-Control Weaknesses
- Management concluded that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 because of material weaknesses involving journal-entry approvals and elevated system access.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q text; the filing does not state that prior guidance was raised, maintained, lowered, or withdrawn.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- NexGel, Inc. reported Q4 2026 revenue of $2.65 million, a decline of 5.6% from $2.81 million in the same period last year. Gross margin decreased to 40.0%, down from 42.3% year-over-year, and the diluted EPS was -0.12…
- 10-K · April 30, 2026
- NexGel, Inc. reported consistent revenues of $3 million for Q4 2025, maintaining this figure across four consecutive quarters, although it still faced operational losses leading to an EPS decline to -0.12. The recent…
- 10-K · March 31, 2026
- The 2025 10‑K reiterates NexGel’s strategy as a contract manufacturer and consumer products developer built on proprietary electron‑beam hydrogel manufacturing (13,500 sq ft facility operating at ~15%–20% capacity and…
- 10-Q · November 12, 2025
- Q3 2025 results were broadly stable revenue‑wise but showed margin and per‑share loss improvement. Revenues were $2.934M (Q3 2025) vs $2.940M (Q3 2024), gross margin expanded to ~42.4% and diluted loss per share…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NXGL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever